

# Hans Neubauer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4055827/publications.pdf>

Version: 2024-02-01

96  
papers

4,169  
citations

156536

32  
h-index

134545

62  
g-index

102  
all docs

102  
docs citations

102  
times ranked

5716  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying Mitotic Kinesins as Potential Prognostic Biomarkers in Ovarian Cancer Using Bioinformatic Analyses. <i>Diagnostics</i> , 2022, 12, 470.	1.3	3
2	Implementing microwell slides for detection and isolation of single circulating tumor cells from complex cell suspensions. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2022, 101, 1057-1067.	1.1	1
3	PGRMC Proteins Are Coming of Age: A Special Issue on the Role of PGRMC1 and PGRMC2 in Metabolism and Cancer Biology. <i>Cancers</i> , 2021, 13, 512.	1.7	16
4	GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. <i>Theranostics</i> , 2021, 11, 7844-7868.	4.6	70
5	The SOX2 Status of Disseminated Tumor Cells in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. <i>Anticancer Research</i> , 2021, 41, 2849-2858.	0.5	1
6	PGRMC1 Promotes Progesterin-Dependent Proliferation of Breast Cancer Cells by Binding Prohibitins Resulting in Activation of ER $\alpha$ Signaling. <i>Cancers</i> , 2021, 13, 5635.	1.7	12
7	Multiparametric Circulating Tumor Cell Analysis to Select Targeted Therapies for Breast Cancer Patients. <i>Cancers</i> , 2021, 13, 6004.	1.7	6
8	Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 111-121.	1.2	22
9	Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression. <i>Breast Cancer Research</i> , 2020, 22, 75.	2.2	30
10	Bioinformatic Identification of a Breast- $\alpha$ -Specific Transcript Profile. <i>Proteomics - Clinical Applications</i> , 2020, 14, 2000007.	0.8	2
11	A Multiplex PCR-Based Next Generation Sequencing-Panel to Identify Mutations for Targeted Therapy in Breast Cancer Circulating Tumor Cells. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 3364.	1.3	4
12	Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1027-1035.	0.8	22
13	Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 355-367.	0.7	10
14	EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. <i>Molecular Cancer Research</i> , 2020, 18, 278-286.	1.5	12
15	Protein complexes including PGRMC1 and actin-associated proteins are disrupted by AG-205. <i>Biochemical and Biophysical Research Communications</i> , 2020, 524, 64-69.	1.0	26
16	53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 930.	1.7	7
17	PGRMC1 effects on metabolism, genomic mutation and CpG methylation imply crucial roles in animal biology and disease. <i>BMC Molecular and Cell Biology</i> , 2020, 21, 26.	1.0	16
18	PGRMC1 phosphorylation affects cell shape, motility, glycolysis, mitochondrial form and function, and tumor growth. <i>BMC Molecular and Cell Biology</i> , 2020, 21, 24.	1.0	36

#	ARTICLE	IF	CITATIONS
19	Diagnostic Leukapheresis Enables Reliable Transcriptomic Profiling of Single Circulating Tumor Cells to Characterize Inter-Cellular Heterogeneity in Terms of Endocrine Resistance. <i>Cancers</i> , 2019, 11, 903.	1.7	24
20	Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients. <i>BMC Cancer</i> , 2019, 19, 1101.	1.1	6
21	Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products. <i>Clinical Chemistry</i> , 2019, 65, 549-558.	1.5	37
22	Role of Circulating Tumor Cells in Breast Cancer Patients. , 2019, , 383-392.		0
23	Filtration based assessment of CTCs and CellSearch <sup>®</sup> based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. <i>BMC Cancer</i> , 2018, 18, 204.	1.1	30
24	Membrane-initiated effects of Serelys <sup>®</sup> on proliferation and apoptosis of human breast cancer cells. <i>Gynecological Endocrinology</i> , 2018, 34, 353-356.	0.7	9
25	EpCAM <sup>high</sup> and EpCAM <sup>low</sup> circulating tumor cells in metastatic prostate and breast cancer patients. <i>Oncotarget</i> , 2018, 9, 35705-35716.	0.8	70
26	Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 1213-1219.	1.1	60
27	Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers. <i>BMC Medical Genomics</i> , 2018, 11, 80.	0.7	13
28	Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap). <i>International Journal of Cancer</i> , 2018, 143, 2584-2591.	2.3	68
29	Magnetic resonance imaging findings of high-grade ductal carcinoma in situ of the male breast: A case report. <i>SAGE Open Medical Case Reports</i> , 2018, 6, 2050313X1878172.	0.2	0
30	Detection of androgen receptor expression in circulating tumor cells of metastatic breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24096-e24096.	0.8	0
31	Isolation and characterization of circulating tumor cells using a novel workflow combining the CellSearch <sup>®</sup> system and the CellCelector <sup>®</sup> . <i>Biotechnology Progress</i> , 2017, 33, 125-132.	1.3	48
32	Enrichment, Isolation and Molecular Characterization of EpCAM-Negative Circulating Tumor Cells. <i>Advances in Experimental Medicine and Biology</i> , 2017, 994, 181-203.	0.8	19
33	Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?. <i>Tumor Biology</i> , 2017, 39, 101042831773151.	0.8	20
34	High Level of Progesteron Receptor Membrane Component 1 (PGRMC 1) in Tissue of Breast Cancer Patients is Associated with Worse Response to Anthracycline-Based Neoadjuvant Therapy. <i>Hormone and Metabolic Research</i> , 2017, 49, 595-603.	0.7	20
35	Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer. <i>Menopause</i> , 2017, 24, 203-209.	0.8	50
36	A Novel Workflow to Enrich and Isolate Patient-Matched EpCAM <sup>high</sup> and EpCAM <sup>low/negative</sup> CTCs Enables the Comparative Characterization of the PIK3CA Status in Metastatic Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1885.	1.8	37

#	ARTICLE	IF	CITATIONS
37	Abstract 1723: Diagnostic leukapheresis results in a significant increase in CTC yield in metastatic breast and prostate cancer. , 2017, , .		1
38	Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer.. Journal of Clinical Oncology, 2017, 35, e17080-e17080.	0.8	1
39	Quantifying HER-2 expression on circulating tumor cells by ACCEPT. PLoS ONE, 2017, 12, e0186562.	1.1	28
40	Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells. Oncotarget, 2017, 8, 72480-72493.	0.8	25
41	Abstract 1733: Automated identification of circulating tumor cells by image analysis. , 2017, , .		0
42	Abstract 3787: EpCAM- and EpCAM+ circulating tumor cells in metastatic prostate and breast cancer patients: a multicenter study. , 2017, , .		0
43	Alterations of the exo- and endometabolite profiles in breast cancer cell lines: A mass spectrometry-based metabolomics approach. Analytica Chimica Acta, 2016, 925, 34-42.	2.6	23
44	Gene expression profiling of single circulating tumor cells in "ovarian cancer" Establishment of a multi-marker gene panel. Molecular Oncology, 2016, 10, 1030-1042.	2.1	75
45	A bead-based western for high-throughput cellular signal transduction analyses. Nature Communications, 2016, 7, 12852.	5.8	84
46	May progesterone receptor membrane component 1 (PGRMC1) predict the risk of breast cancer?. Gynecological Endocrinology, 2016, 32, 58-60.	0.7	26
47	Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?. Oncotarget, 2016, 7, 26454-26464.	0.8	11
48	Gene expression profiling of single circulating tumor cells in ovarian cancer: Establishment of a multi-marker gene panel.. Journal of Clinical Oncology, 2016, 34, e17085-e17085.	0.8	0
49	Abstract 2492: Do disseminated tumor cells with stem cell character after therapy predict prognosis in primary ovarian cancer. , 2016, , .		0
50	Abstract 1532: The isolation of CTC from diagnostic leukapheresis. , 2016, , .		1
51	Exometabolom analysis of breast cancer cell lines: Metabolic signature. Scientific Reports, 2015, 5, 13374.	1.6	24
52	Suppression of Early Hematogenous Dissemination of Human Breast Cancer Cells to Bone Marrow by Retinoic Acid"Induced 2. Cancer Discovery, 2015, 5, 506-519.	7.7	45
53	Oestretrol stimulates proliferation and oestrogen receptor expression in breast cancer cell lines: Comparison of four oestrogens. European Journal of Contraception and Reproductive Health Care, 2015, 20, 29-35.	0.6	12
54	EpCAM-Independent Enrichment of Circulating Tumor Cells in Metastatic Breast Cancer. PLoS ONE, 2015, 10, e0144535.	1.1	92

#	ARTICLE	IF	CITATIONS
55	Expression of Stem Cell and Epithelial-Mesenchymal Transition Markers in Circulating Tumor Cells of Breast Cancer Patients. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	86
56	Genomic High-Resolution Profiling of Single CKpos/CD45neg Flow-Sorting Purified Circulating Tumor Cells from Patients with Metastatic Breast Cancer. <i>Clinical Chemistry</i> , 2014, 60, 1290-1297.	1.5	74
57	Various Factors Contributing to Tumor Dormancy: Therapeutic Implications in Breast Cancer. , 2014, , 51-57.		0
58	Analysing the mutational status of <i>PIK3CA</i> in circulating tumor cells from metastatic breast cancer patients. <i>Molecular Oncology</i> , 2013, 7, 976-986.	2.1	72
59	Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells. <i>Gynecological Endocrinology</i> , 2013, 29, 160-162.	0.7	19
60	Medroxyprogesterone acetate-driven increase in breast cancer risk might be mediated via cross-talk with growth factors in the presence of progesterone receptor membrane component-1. <i>Maturitas</i> , 2013, 76, 129-133.	1.0	21
61	SOX2 Expression and Prognostic Significance in Ovarian Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 358-367.	0.9	37
62	Overexpression of progesterone receptor membrane component 1. <i>Menopause</i> , 2013, 20, 504-510.	0.8	30
63	The persistence of disseminated tumor cells after systemic therapy and their influence on prognosis in early breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1030-1030.	0.8	0
64	Dormancy in breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2012, 4, 183.	1.0	25
65	Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay. <i>BMC Cancer</i> , 2012, 12, 308.	1.1	17
66	Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells. <i>Gynecological Endocrinology</i> , 2012, 28, 863-866.	0.7	30
67	Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay. <i>Investigational New Drugs</i> , 2012, 30, 1750-1755.	1.2	5
68	Detection of disseminated tumor cells in bone marrow as an independent prognostic factor in primary ovarian cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5042-5042.	0.8	2
69	Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, e21003-e21003.	0.8	0
70	The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells. <i>Menopause</i> , 2011, 18, 845-850.	0.8	42
71	ATP chemosensitivity testing of new antitumor duplex drugs linking 3'-C-ethynylcytidine (ECyd) and 2'-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof. <i>Investigational New Drugs</i> , 2011, 29, 506-513.	1.2	8
72	Molecular detection of breast cancer metastasis in sentinel lymph nodes by reverse transcriptase polymerase chain reaction (RT-PCR): identifying, evaluating and establishing multi-marker panels. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 833-844.	1.1	18

#	ARTICLE	IF	CITATIONS
73	Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. <i>BMC Cancer</i> , 2011, 11, 42.	1.1	162
74	New insight on a possible mechanism of progestogens in terms of breast cancer risk. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2011, 6, 185-92.	0.3	10
75	Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2011, 6, 211-4.	0.3	1
76	Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection. <i>BMC Cancer</i> , 2009, 9, 104.	1.1	65
77	Disseminated Tumor Cells in Bone Marrow May Affect Prognosis of Patients With Gynecologic Malignancies. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 948-952.	1.2	49
78	A laminin-rich basement membrane matrix influences estrogen receptor beta expression and morphology of MDA-MB-231 breast cancer cells. <i>Oncology Reports</i> , 2009, 21, 475-81.	1.2	6
79	HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. <i>Anticancer Research</i> , 2009, 29, 4019-24.	0.5	44
80	Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer. <i>Analytica Chimica Acta</i> , 2008, 618, 29-34.	2.6	41
81	ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. <i>Breast Cancer Research</i> , 2008, 10, R76.	2.2	82
82	Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. <i>Breast Cancer Research</i> , 2008, 10, R85.	2.2	113
83	Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. <i>Anticancer Research</i> , 2008, 28, 949-55.	0.5	25
84	Changes in tumour biological markers during primary systemic chemotherapy (PST). <i>Anticancer Research</i> , 2008, 28, 1797-804.	0.5	50
85	Proteomic Expression Profiling of Breast Cancer. , 2007, 176, 89-120.		6
86	Metabolic signature of breast cancer cell line MCF-7: profiling of modified nucleosides via LC-IT MS coupling. <i>BMC Biochemistry</i> , 2007, 8, 25.	4.4	40
87	The Mitochondrial DNA Common Deletion Is Present in Most Basal and Squamous Cell Carcinoma Samples Isolated by Laser Capture Microdissection but Generally at Reduced Rather than Increased Levels. <i>Journal of Investigative Dermatology</i> , 2007, 127, 486-490.	0.3	16
88	Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer. <i>Breast Cancer Research</i> , 2006, 8, R60.	2.2	48
89	Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2006, 98, 179-184.	1.1	123
90	Breast cancer proteomics by laser capture microdissection, sample pooling, 54-cm IPG IEF, and differential iodine radioisotope detection. <i>Electrophoresis</i> , 2006, 27, 1840-1852.	1.3	67

#	ARTICLE	IF	CITATIONS
91	JAK2 contributes to the intrinsic capacity of primary hematopoietic cells to respond to stem cell factor. <i>Experimental Hematology</i> , 2004, 32, 149-156.	0.2	28
92	Erythropoiesis in the absence of janus-kinase 2: BCR-ABL induces red cell formation in JAK2 <sup>-/-</sup> hematopoietic progenitors. <i>Blood</i> , 2001, 98, 2948-2957.	0.6	27
93	Partial Impairment of Cytokine Responses in Tyk2-Deficient Mice. <i>Immunity</i> , 2000, 13, 549-560.	6.6	375
94	Jak2 Deficiency Defines an Essential Developmental Checkpoint in Definitive Hematopoiesis. <i>Cell</i> , 1998, 93, 397-409.	13.5	908
95	Listeriosis in p47phox <sup>-/-</sup> and TRp55 <sup>-/-</sup> Mice: Protection Despite Absence of ROI and Susceptibility Despite Presence of RNI. <i>Immunity</i> , 1997, 7, 419-432.	6.6	119
96	Jak2 Is an Essential Tyrosine Kinase Involved in Pregnancy-Mediated Development of Mammary Secretory Epithelium. , 0, .		12